Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 171

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 171
---
 FDIC insurance as of September 30, 2024 was $ 0. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Marketable Securities

Our investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading of debt securities are charged to income.

The marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding balance of $ 0and $ 2.9million as of September 30, 2024 and December 31, 2023, respectively. During the three months ended September 30, 2024 and 2023, the Company recognized interest income of $ 2,524and $ 20,765, realized gains of $ 56,398and $ 0, and unrealized losses of $ 42,898and unrealized gains of $ 9,606, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized interest income of $ 38,135and $ 56,720, realized gains of $ 100,118and $ 1,744, and unrealized loss of $ 71,568and unrealized gain of $ 21,134, respectively.

Fair Value of Financial Instruments

The Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:

| ● | Level                                                                                                                                  
 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.                                     |
| ● | Level                                                                                                                                  
 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.                                |
| ● | Level                                                                                                                                  
 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values 
 are determined using pricing models,